Clinically, PARP inhibitors have improved outcomes compared with conventional therapy for both advanced and early-stage BRCA1/2-mutated breast cancer as well as ovarian and prostate cancers by extending disease-free and overall survival7. The gene discussed is BRCA1; the disease is Familial prostate cancer.